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The role of protein tyrosine kinases in the expression of interleukin-lg (IL-1s) gene in response to phorbol esters (PMA) in THP-1 cell line was 
investigated. Genistein. a specific tyrosine kinase inhibitor, inhibited PMA Induced IL-lb protein and mRNA levels in THP-1 cells. Genistein did 
not have a significant effect on PMA induced activity in transient ransfection assays using reporter gene constructs containing the PMA responsive 
sequence of the IL-I/I gene hnked to IL-l/I promoter, or five repeats of PMA responsive sites (AP-I sites) in front of a thymidine kmase promoter. 
This indicates that the tyrosine kinase activity required for the PMA induced IL-l/3 expression is coupled downstream from or functions independent 
of the PMA Induced AP-1 activity. 
Interleukin-I/?; THP-1 cell line; Phorbol ester; Tyrosme kinase; Protein kinase C; AP-I 
1. INTRODUCTION 
Interleukin-1 (IL-l) is a cytokine mainly produced by 
cells of the monocyte/macrophage lineage (reviewed in 
[l]). Two distinct molecular forms, IL-la and IL-l/?. 
have been characterized and their genes cloned and se- 
quenced [2]. These molecules possess many biological 
activities in immune and inflammatory responses, and 
in normal hematopoiesis. Mature monocyte/macroph- 
ages do not normally express IL-l genes, but their ex- 
pression can be induced by a variety of activators [3]. 
The signal transduction pathways leading to the ex- 
pression of IL-lp gene in monocytes/macrophages have 
been partially characterized. Activation of protein ki- 
nase C (PKC) (a serine-threonine kinase) has been re- 
ported to play an important role in the induction of 
IL-l/? expression in different cell types and after differ- 
ent stimuli [4,5]. PKC regulates transcription by activat- 
ing different transcription factors, which bind to specific 
c&elements on PKC activated genes (reviewed in [6]). 
The best characterized PKC dependent pathway is me- 
diated by the fos/jun transcription factor complex (acti- 
vating protein 1; AP-1 complex), which binds to the 
phorbol ester response element (AP-1 binding site) on 
PKC inducible genes [7]. AP-1 is composed of heterod- 
imers of the jun and fos proto-oncogene families or 
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homodimers of thejun family. AP-1 activity is regulated 
both at the level of transcription as well as by post- 
translational modifications of pre-existing AP-1 [6]. It 
has recently been demonstrated that a 180 base pair 
long enhancer sequence in the IL-la gene, which is re- 
quired for the phorbol ester induced IL-la expression, 
contains a putative AP-1 binding site [S]. 
Another major protein kinase family, tyrosine ki- 
nases, is involved in the signal transduction of many 
receptor systems and in the proliferation and differenti- 
ation of normal and malignant cells (for a review see 
[9]). Tyrosine kinases can be divided into two groups; 
to those expressing extracellular ligand binding do- 
mains and an intracellular tyrosine kinase domain (e.g. 
receptors for various polypeptide growth factors like 
PDGF receptor) and to those residing entirely intracel- 
lularly (e.g. members of the src, feslfps and abl gene 
families). The increase in general tyrosine kinase activ- 
ity [lo] and in the expression of certain members of sr( 
and fes family genes during myeloid differentiation and 
monocyte activation [ll-131 first suggested that tyro- 
sine kinases also have a role in mediating activation 
signals in differentiated monocytes. Increased protein 
phosphorylation on tyrosine in response to bacterial 
LPS was recently reported in monocyte/macrophages 
[14]. A role for tyrosine kinases in the regulation of IL-l 
expression has also been demonstrated. Granulocyte- 
macrophage colony stimulating factor (GM-CSF), 
which activates protein tyrosine phosphorylation, in- 
duces IL-l production in human mononuclear cells [ 151, 
and IL-la expression induced via MHC Class II mole- 
cules is inhibited by tyrosine kinase inhibitors in THP-1 
cells [16] and in human monocytes (Palkama and 
Hurme, Hum. Immunol., in press). 
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In addition to direct activation of PKC, protein phos- 
phorylation on tyrosine has been reported after phorbol 
ester stimulation in various cell types [17-191. In this 
work we demonstrate that tyrosine kinase activity is 
involved in phorbol ester induced IL-l#I expression in 
the monocytic cell line THP-1. The coupling of the tyro- 
sine kinase activity involved in phorbol ester induced 
IL-I/I expression to phorbol ester induced AP-1 en- 
hancer activity, was also investigated. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Phorbol 12-my&ate-13-acetate (PMA) was purchased from Sigma 
Chemical Co. (St. Louis, MO). Protein kinase C inhibitor H7 (I-[5 
isoquinolonesulfonyl]-2-methylpiperazine dihydrochloride) and pro- 
tein kinase A (PKA) inhibitor HA 1004 (N-(2-guanidinoethyl)-5- 
isoquinoline-sulfonamide hydrochloride) were purchased from Sei- 
kagaku Kogyo Co. (Tokyo, Japan). Genistein was purchased from 
Gibco Research Products Life Technologies Inc. (Gaithersburg, MD). 
2.2. Cell cultures 
The THP-1 cell line was obtained from The American Type Culture 
Collection (Rockville, MD). The cells were cultured in RPM1 1640 
medium (Flow Laboratories, Irvine, Renfrewshire, UK) containing 10 
mM HEPES, 2 mM L-glutamine, 70pM 2-mercaptoethanol, antibiot- 
ics and 10% fetal calf serum (Flow). The cells were tested monthly for 
Mycoplasma and were found to be negative. 
2.3. IL-l/l protein induction and analysis 
During the exponential growth phase, THP-I cells were cultured 
with the indicated stimulators at IO6 cells/ml in 24-well plates (Costar, 
Cambridge, MA). After 24 h cells were collected with the supernatants 
to determine total (intracellular, cell-associated and secreted) IL-l/I 
produced. Cells were disrupted with three cycles of freezing and thaw- 
ing and all samples were stored at -20°C. IL-l/I contents of the 
samples was measured by an IL-l/3 ELISA (Cistron, Pine Brook, NJ) 
according to the manufacturer’s instructions. 
2.4. RNA isolation and analysu 
0.5 x lo6 THP-1 cells/ml were cultured in 75 cm’ tissue culture flasks 
(Costar, Cambridge. MA) and stimulated with the indicated stimula- 
tors. After 6 h cells were harvested and total cellular RNA was isolated 
by guanidium isothiocyanate lysis and CsCl centrifugation [20,21]. 
The RNA isolated was quantitated spectrophotometrically and 30 pg 
samples were size-fractionated on 1.2% agarose-formaldehyde g ls, 
transferred to a nylon membrane (Pall, Glen Cove, NY), dried and 
baked at 80°C. The IL-1B cDNA probe (HU-IL-l/I, pcDSRa) used 
was provided by Dr. Kari Varkila (DNAX Research Institute, Palo 
Alto, CA). The RNA levels on the nylon membranes were also quan- 
titated by using a constant probe, glyceraldehyde phosphate dehydro- 
genase (pRGAPDH-13), which was a gift from Dr. Kari Alitalo (Dept. 
Pathology, University of Helsinki). The IL-1s cDNA insert (BamHI- 
digested fragments from the HU-IL-1B plasmid) and the GAPDH 
insert (&I-digested fragments from pRGAPDH-13) were labeled 
with “P using a random-primed DNA labeling kit purchased from 
Boehringer-Mannheim GmbH, (Mannheim, Germany). Prehybridiza- 
tions and hybridizations were performed in a solution containing 50% 
formamide, 5x Denhardt’s solution, 5x SSPE and 0.5% SDS. Filters 
were washed in lx SSC plus 0.1% SDS, twice for 30 min at room 
temperature and once at 60°C for 30 min. Subsequently, the filters 
were exposed to Kodak AR X-Omat films at -70°C with intensifying 
screens. 
2.5. Transfections 
DNA was introduced into THP-1 cells by electroporation as de- 
scribed by Pahl et al. [22]. Briefly, the medium was changed and the 
cells were grown at the density of 0.2 x 106/ml. 1624 h later the cells 
were washed twice with RPMI-1640 and resuspended at 28 x 106/ml 
in RPMI-1640.2Oyg ofplasmid DNA in 50~1 RPMI-1640 was mixed 
with 0.5 ml of cell suspension and placed into a 0.4 cm electroporation 
cuvette. The cells were incubated 5 min at room temperature prior to 
electroporation at 960 fluF and 300 V (Bio-Rad Laboratories, 
Richmond, VA). 
After electroporation the cuvettes were transferred into an ice bath 
for 5 min. After transfection the cells were cultured at lO”/ml with the 
indicated stimulators. Two different CAT constructs were used (Fig. 
1). Cal-TREx5/TK-CAT [7], which contains five copies of the AP-I 
binding site from the human collagenase gene, the thymidine kinase 
promoter of Herpes simplex virus and the chloramphenicol acetyl 
transferase (CAT) reporter gene, was a generous gift of Dr. M. Karin 
(Department of Pharmacology, University of California. San Diego, 
CA). The IL-I/I-X-CAT was a gift from Dr. G. Bensi (Sclavo Research 
Centre, Siena, Italy). It contains two 234 bp repeats of the phorbol 
ester responsive IL-l/I enhancer located between positions -2982 and 
-2748 linked to IL-I/I promoter from 132 bp immediately upstream 
of the transcriptional start site to +548 of the second exon of the IL-l/I 
gene, SV-40 promoter and enhancer and CAT gene [8] 
2.6. Assay of CAT act&J 
24 h after stimulation, the cells were harvested to CAT assay. The 
cells were washed twice in PBS and resuspended in 0.25 M Tris-HC1, 
pH 7.4. Cell extracts were prepared by four cycles of freezing and 
thawing. The nonchromatographic CAT assay was performed as pre- 
viously described [23]. Incubation mixture contained 20 ~1 of 8 mM 
chloramphenicol, cell extract (30 pug), 20 ~1 of [‘4C]acetyl coenzyme A 
(5 flCi/ml). 0.25 M Tris-HCI, pH 7.4, to bring the reaction volume to 
0.1 ml. Solid [“‘Clacetyl coenzyme A (Amersham) was dissolved m 
water (50 pCi/ml) and diluted 1:lO with 0.5 mM unlabeled enzyme 
(Boehringer-Mannheim) before use. Incubation was performed at 
37°C for 1 h. The reaction was stopped with 0.6 ml of cold ethyl 
acetate, which was also used to extract the chloramphemcol. The 
organic layer was mixed with 3.0 ml of Optiscint Hisafe (Wallac. 
Turku, Finland) and radioactivity was determined by liquid scintilla- 
tion B-counter. Under these incubation conditions the reaction was at 
the linear range as determined with purified CAT enzyme (Promega 
Corp., Madison, WI). 
3. RESULTS 
3.1. The effect of genistein, an inhibitor of protein tyro- 
sine kinases, on IL-ID production in THP-1 cells 
We examined the possible role of tyrosine kinase ac- 
tivity in the regulation of IL-l/? protein production in 
response to phorbol esters in THP- 1 cells. THP-1 cell 
line is derived from a patient with monocytic leukemia 
[24] and it resembles normal monocytes in its ability to 
produce IL-I in response to various stimulators (e.g. 
LPS and phorbol esters [25]). THP- 1 cells were preincu- 
bated for 30 min with different concentrations of genis- 
tein, a specific inhibitor of tyrosine protein kinase activ- 
ity of both receptor type- (e.g. EGF-receptor) and intra- 
cellular (e.g. pp60”+” tyrosine kinases [26], before leav- 
ing the cells unstimulated or stimulating them with the 
optimal concentration (10 rig/ml) of PMA for 24 h. 
After that cultures were harvested and analyzed for 
their IL-l/I protein content in an IL-IB specific ELISA 
as described in section 2. Genistein concentration de- 
pendently inhibited PMA induced IL-lp production 
(Table I). 
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Fig. 1. Diagrammatic representation of the plasmids used. Col- 
TRExYTK-CAT: five copies of the PMA responsive elements of the 
human collagenase gene (AP-1 binding sites) are linked to the 
pBLCAT-2 plasmid containing the Herpes simplex virus thymidine 
kinase promoter and CAT coding gene. IL-lb-X-CAT: two copies of 
the PMA responsive sequence of the IL-lp gene between sequences 
-2,982 and -2,748 (234 bp boxes) are linked to the IL-lb promoter 
(from -132 to +548 of the second exon) and pAlOCAT-2 plasmid 
containing the SV40 promoter and enhancer and CAT coding gene. 
Stippled box: the upstream sequence of the murme c-mos gene (UMS) 
used as the transcription terminator. 
3.2. The effect of tyrosine kinase inhibition on phorbol 
ester mediated IL-ID RNA expression in THP-1 cell 
line 
We then investigated, whether the tyrosine kinase ac- 
tivity involved in IL-l/? expression could also be seen at 
the mRNA level. THP-1 cells were preincubated with 
the indicated concentrations of genistein for 30 min and 
then stimulated with 10 ng/ml PMA for 6 h. Cells were 
then harvested and total cellular RNA was isolated and 
analyzed for the expression of IL-l/? mRNA. Again, 
genistein dose dependently inhibited IL-l/I mRNA lev- 
els induced by PMA in THP-1 cells (Fig. 2). 
3.3. Genistein does not modulate the PMA-induced AP-1 
enhancer activity 
To localize the site of action of the tyrosine kinase 
activity involved in IL-la expression, the effect of genis- 
tein in THP-1 cells transiently transfected with Col- 
TRExS/TK-CAT, a reporter gene construct containing 
5 repeats of the TRE-element upstream of the Herpes 
simplex virus-thymidine kinase-promoter CAT gene 
(Fig. 1). As expected, PMA strongly elevated AP-1 en- 
hancer activity, the increase was 6.9-fold when com- 
pared to unstimulated cells in 4 independent experi- 
ments (Fig. 3A). 30 ,ug/ml genistein did not have a sig- 
nificant inhibitory effect on the PMA induced AP-1 
enhancer activity. The serine-threonine kinase inhib- 
itors H7 and HA 1004 were used as controls. 25 PM H7, 
a preferential PKC inhibitor, completely inhibited PMA 
induced AP-1 enhancer activity, while the same concen- 
tration of HA 1004, a preferential protein kinase A 
inhibitor with a weak PKC inhibitory effect, partially 
inhibited PMA induced AP-1 activity. The serine-thre- 
onine kinase inhibitors used clearly inhibited AP-1 ac- 
tivity, while genistein at concentrations which effec- 
tively inhibited IL-l/3 expression, remained uneffective. 
This indicates that the inhibitory effect of genistein on 
IL-lp expression is not mediated via unspecific inhibi- 
tion of serine-threonine kinases. 
To determine the effect of genistein on the reporter 
gene construct containing the phorbol ester responsive 
sequences of the IL-l/3 gene, we transfected THP-1 cells 
with IL-lp-X-CAT, which contains two repeats of the 
phorbol ester responsive IL- l/3 enhancer linked to IL- lp 
promoter (Fig. 1) [8]. 10 @ml PMA induced a ca. 
4-fold increase in CAT activity of IL-lp-X-CAT trans- 
fected cells, which again was not inhibited by 30 &ml 
genistein (Fig. 3B). 
4. DISCUSSION 
In this study we demonstrate that tyrosine kinases 
functioning downstream from or independent of PKC 
dependent AP-1 activation are involved in the phorbol 
ester mediated IL-l/? expression in monocytic cells. 
Activation of PKC is known to play an important 
role in phorbol ester induced IL-l/? expression [4,5]. In 
addition to directly activating PKC [27], phorbol esters 
have been shown to induce protein phosphorylation on 
tyrosine in various cell types [l l-131. We have also dem- 
onstrated that PMA induced protein phosphorylation 
on tyrosine in THP-1 cells, when determined with an- 
tiphosphotyrosine immunoblotting of whole cell lysates 
(results not shown). To investigate the role of tyrosine 
Table I 
The effect of genistein. a tyrosine kinase Inhibitor. on interleukin-l/7 





PMA 10 @ml 3,398 100 
PMA 10 &ml + gemstein 30 &ml 625 25? 12 
PMA 10 @ml+ genistem 20 ,&ml 1,934 64 f 28 
PMA 10 &ml+ genistein 10 ,&gIml 3,423 121 * 33 
THP-1 cells (lo6 cells/ml) were preincubated for 30 min with the 
indtcated concentrations of genistein and then stimulated with PMA. 
After 24 h the cultures were harvested and their IL-1B content was 
measured by IL-I/3 specific ELISA assay. 
d The data is shown from a smgle expertment. 
bMean percent of IL-lb production (+S.D.). when compared to PMA 
stimulation, of four independent experiments. 
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none 
PMA 
PMA + genistein 30 pg/ml 
PMA + genistein 20 pg/ml 
PMA + genistein 10 pglml 
genistein 30 pg/ml 
Fig. 2. The effect of genistein on phorbol ester mediated IL-IS expres- 
sion in THP-1 cells. 0.5 x lo6 cells/ml THP-1 cells were cultured with 
media alone or with the indicated concentrations of the tyrosine kinase 
inhibitor genistein for 30 min. After that cells were left unstimulated 
or stimulated with 10 ng/ml PMA. After 6 h cells were harvested and 
total cellular RNA was isolated and analyzed for IL-IS expression. 
The experiment was repeated three times with identical results. 
kinase activation in IL-l/I expression, the effect of gen- 
istein, a specific tyrosine kinase inhibitor in concentra- 
tions up to 40 &ml [26], on phorbol ester induced 
IL-l/? production was determined. Genistein concentra- 
tion dependently inhibited PMA induced IL-1B protein 
production and IL-1B RNA expression in THP-1 cells, 
indicating that protein tyrosine kinases are involved in 
phorbol ester mediated IL-l/? expression. 
PKC and tyrosine kinase signal transduction path- 
ways are known to interact in several cellular systems. 
Attenuation of receptor tyrosine kinase activity by PKC 
has been demonstrated in EGF-receptor [28]. In T lym- 
phocytes tyrosine phosphorylation is required for phos- 
pholipase Cy mediated inositol phospholipid hydrolysis 
and subsequent PKC activation in T-cell receptor medi- 
ated activation. Members of the src family, ~59’~” asso- 
ciated to the TCR/CD3 complex and ~56’“~ associated 
to the CD4/CD8 molecule are the likely candidates to 
mediate this tyrosine phosphorylation signal (reviewed 
in [29]). A similar tyrosine kinase mediated PKC activa- 
tion cascade has been demonstrated in signalling via 
MHC class II molecules in lymphocytes [30]. Data de- 
monstrating PKC mediated tyrosine kinase activation 
also exists, since tyrosine phosphorylation of lymphoid 
microtubule associated protein-2 kinase (MAP-2 ki- 
nase) is dependent on PKC [31,32]. 
It has recently been shown that an inducible enhancer 
sequence, which contains a putative AP-1 binding site, 
is required for IL-1s expression in response to phorbol 
esters in myeloid cells [8]. Activation of AP-1 via PKC 
is well characterized [6]. We wanted to determine, 
whether the tyrosine kinase involved in phorbol ester 
induced IL-l/? expression is coupled to phorbol ester 
mediated AP-1 activation. The effect of genistein in 
phorbol ester induced AP-1 activity was investigated 
using two different reporter gene constructs; IL-l/?-X- 
CAT, containing the phorbol ester responsive sequence 
of IL-1B gene coupled to IL-l/3 promoter and CAT 
gene, and Col-TRExS/TK-CAT, which contains 5 re- 
peats of AP-1 binding sites from human collagenase 
gene in front of the thymidine kinase promoter and 
CAT gene. The same concentration of genistein (30 pug/ 
ml), which inhibited IL-l/? expression in THP-1 cells, 
did not have a significant inhibitory effect on phorbol 
ester induced CAT activity in either reporter gene con- 
struct. The serine-threonine kinase inhibitors H7 and 
HA 1004, used as specificity controls for genistein, 
B ‘I T 
Fig. 3. The effect of genistein on PMA induced AP-1 enhancer activity in THP-1 cells. (A) THP-1 cells were transfected with the Col-TRExSfTK- 
CAT plasmid. Cells were either left unstimulated or cultured for 30 min with the indicated inhibitors: 25 ,uM H7, 25 ,uM HA 1004 or 30 pg/ml 
genistein. After transfections cells were either left unstimulated or stimulated with 10 ng/ml PMA. After 24 h cells were lysed and CAT activity 
determined. The data shown are expressed as mean fold of increase (+S.D.) when compared to unstimulated cells of 4 independent experiments. 
(B) THP-I cells were transfected with IL-l/I-X-CAT plasmid. After transfections cells were cultured with no stimulators or 30 pg/ml genistein for 
30 min. After that cells were either left unstimulated or cultured with 10 @ml PMA for 24 h and CAT activity was determined. The data shown 
are expressed as mean fold of increase (+S.D.) when compared to unstimulated cells of 4 Independent experiments. 
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clearly inhibited PMA induced AP-1 CAT activity. Our 
data indicates that genistein inhibitable tyrosine kinases 
are not involved in phorbol ester induced AP-1 en- 
hancer activity. 
Little data on the role of tyrosine kinases in the regu- 
lation of transcriptional activation exists. Recently the 
activation of the transcription factor interferon-ol-stim- 
ulated gene factor 3 (ISGF3) via tyrosine phosphoryla- 
tion by interferon-a and -y was reported [33]. This is the 
first direct evidence of tyrosine kinases activating tran- 
scription factors. The transcriptional activation of IL- 
Ip expression is still poorly characterized. In addition 
to the phorbol ester responsive element located between 
positions -2,982 and -2,795 upstream of the IL-l/? 
transcriptional start site, elements located in the IL-l,6 
gene enhancer/promoter regions have been reported to 
regulate both the constitutive and inducible IL-ID ex- 
pression in monocytic cells [8.34]. However, there has 
been no evidence on the role of tyrosine kinases in this 
regulation. We have preliminary data showing that gen- 
istein strongly reduces the constitutive expression of a 
reporter gene construct containing the region between 
- 1,100 and + 11 base pairs of the IL- l/I gene, thus sug- 
gesting that constitutive, rather than PMA inducible 
tyrosine kinases are required for the IL-l/3 expression. 
We are currently trying to localize the target sequence 
of the tyrosine kinase activity within this region. 
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